Category: Our pipeline overview
Stars explained 2
Stars explained 1
Oral PGF2α receptor antagonist
Oral GnRH receptor antagonist
ObsEva is advancing three product candidates through clinical development across a total of four indications.
Advancing Novel Therapeutics for Women’s Reproductive Health
ObsEva is advancing a pipeline of orally administered, clinical-stage innovative compounds to treat women’s reproductive health conditions.
We are currently conducting three international clinical research studies. Read more